摘要
聚氨基葡糖作为载体与放射性核素166Ho或者153Sm螯合成复合物,通过间质给药后,主要滞留于注射部位的病变组织,通过辐射损伤达到治疗目的,而其他组织器官分布较少,是一种理想的内照射治疗药物。
As a carrier, chitosan may form a compound 166Ho-CHICO, 153Sm-CHICO with 166Ho or 153Sm. Most of the compound retains in the lesional tissue of the injection site by the interstitial administration, while the distribution of the compound in other tissue and organ is less. Using radiation injury will achieve to the treatment purpose. The complex is regarded as an ideal inter-radiation drug.
出处
《国外医学（放射医学核医学分册）》
2003年第6期245-247,共3页
Foreign Medical Sciences(Section of Radiation Medicine and Nuclear Medicine)
基金
江苏省卫生厅科研基金资助课题(H200117)
